August 14, 2019

Do you have primary IgA nephropathy?

You may qualify to participate in an active-control treatment study of the efficacy and safety of Sparsentan, funded by Retrophin Incorporated. Qualifying participants must be over the age of 19 years old, not on dialysis or have received a previous transplant, and have had a renal biopsy confirming diagnosis. Participants will be compensated. For more information, please contact Laura Latta via phone number 205-975-8638 or email at